Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype
Open Access
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 129 (2) , 150-160
Abstract
No abstract availableKeywords
Funding Information
- Shire Human Genetic Therapies, Inc
- Shire Human Genetic Therapies
- Amicus
- Sanofi Genzyme
- Shire Human Genetic Therapies
- Shire Human Genetic Therapies
- Sanofi Genzyme
- Sanofi Genzyme
This publication has 30 references indexed in Scilit:
- Prevalence of Chronic Kidney Disease and Associated Risk Factors, and Risk of End-Stage Renal Disease: Data from the PREVADIAB StudyNephron Clinical Practice, 2011
- Neuropsychiatric symptoms and brain structural alterations in Fabry diseaseEuropean Journal of Neurology, 2011
- Toward a consensus in the laboratory diagnostics of Fabry disease ‐ recommendations of a European expert groupJournal of Inherited Metabolic Disease, 2011
- Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newbornsJournal of Human Genetics, 2010
- Frequency of Fabry disease in male and female haemodialysis patients in SpainBMC Medical Genetics, 2010
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseProceedings of the National Academy of Sciences, 2008
- Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycinBiochemical Journal, 2007
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 2001